Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NASH Drug Development Guidance Encourages Sponsors To Adopt Innovative Trial Designs

Executive Summary

Although guidance appears to be free of surprises, US FDA once again made a push for sponsors to adopt seamless trial designs.
Advertisement

Related Content

Gilead’s FXR Agonist Posts Questionable Results In NASH, But Offers Hope In PSC
Woodcock Hopes I-SPY 2 Trial Is 'Blazing The Trail' For Future Adaptive Design Uptake
“One Continuous Trial” In Oncology: US FDA Offers Guidance And Encouragement
Pfizer Working To Catch Up In NASH With Fat-Reducing Compounds
New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib
Galectin Offers Subgroup Approach For Struggling NASH Candidate
Galectin Hopes To Set Surrogate Endpoints For NASH Cirrhosis, Despite Trial Failure
'Clean Label' For Intercept's Ocaliva In PBC Bodes Well For NASH Claim

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel